With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.492431-11-5,1-Boc-4-(6-Chloropyridazin-3-yl)piperazine,as a common compound, the synthetic route is as follows.
A mixture of tert-butyl 4- (6-chloropyridazin-3-yl)piperazine-l-carboxylate (0.060 g, 0.20 mmol), compound 83 (0.054 g, 0.20 mmol), Xantphos (0.017 g, 0.030 mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), and sodium tert-butoxide (0.029 g, 0.30 mmol) in dioxane was purged with nitrogen gas for 1 minute. The reaction was heated at 12O0C for 6 hours and then cooled to room temperature. The solvent was removed by filtration. The residue was washed with 2 x ImI dioxane. The product was then dissolved in 1OmL methanol/DCM (1 :1) and concentrated. The crude material was re-dissolved in 4mL methanol and purified on a C-18 reversephase column (150 x 30 mm, 4 micro) using Mass directed preperative HPLC and gradient elution of acetonitrile in water containing 0.1%TFA to give the title compound 162. LCMS-ESI (POS), M/Z, M+l: 532.3
492431-11-5, 492431-11-5 1-Boc-4-(6-Chloropyridazin-3-yl)piperazine 21925370, apyridazine compound, is more and more widely used in various fields.
Reference£º
Patent; AMGEN INC.; WO2009/85185; (2009); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem